177 Lu-Folate Therapy in Combination with Pemetrexed
Introduction
Targeted radionuclide therapy has shown impressive results for the palliative treatment of several cancer diseases. It is based on the use of particle-emitting radioisotopes (e.g. 177 Lu 90 The development of new targeting strategies for the treatment of further tumor types is of high interest and would have a critical impact on the future management of these cancer diseases. In this respect the folate receptor (FR) is an attractive target as it has been identified specifically associated with a variety of cancer types, such as ovarian, endometrial, lung, brain, breast and colorectal cancer (4, 5) . The vitamin folic acid has been used as a targeting ligand because it binds to the FR with high affinity followed by endocytotic internalization of the therapeutic payload into cancer cells (6) . While folic acid conjugates of highly toxic chemotherapeutics have been successfully employed in clinical trials (7, 8) , application of therapeutic folic acid radioconjugates is currently being developed in preclinical studies.
Substantial expression of the FR in the proximal tubule cells of the kidneys results in commonly high and specific renal uptake of folate based radioconjugates (9, 10) . As a consequence there is an inherent risk of damage to the kidneys by particle-radiation. However, we have shown in several preclinical studies that administration of the antifolate pemetrexed (PMX) resulted in a tremendous reduction of the radiofolate's retention in the kidneys while accumulation in tumor xenografts remained unaffected (11) (12) (13) . The exact mechanism of this interaction is still not completely clear. However, in numerous preclinical studies we observed an interrelation between the kidney reducing effect and the time point of pre-injected PMX (14) as well as the molar (15) . On the other hand, the reduced kidney uptake of radiofolates was not a result of PMX's antifolate activity as the effect was maintained even if PMX was applied in combination with the antidote thymidine (16) . These facts suggest that PMX's kidney reducing effect is based on a competition among PMX and the folate radioconjugate for FR binding sites in the kidneys.
PMX is a multi-targeted antifolate which is clinically approved for the treatment of pleural mesothelioma and non-small cell lung cancer in combination with cisplatin (17) (18) (19) . Moreover, PMX is currently being tested in a number of clinical trials for the treatment of several other cancer types (reviewed in (20) ), among those is also ovarian cancer (21) . It has been used in combinations with gemcitabine, tyrosine kinase inhibitors, antibodies or even external radiation are used (22) (23) (24) . A combination of PMX with external radiotherapy was based on the observation that PMX acts as a radiosensitizing agent in variable types of cancer cells in vitro and in vivo (25) (26) (27) (28) .
We hypothesized that PMX would have a dual role if it was combined with therapeutic folate radioconjugates. Firstly, it was expected to prevent radionephropathy by reducing the absorbed radiation dose of folate radioconjugates in the kidneys. Secondly, PMX was believed to enhance the therapeutic efficacy of folate-based radionuclide tumor therapy by its action as a chemotherapeutic and radiosensitizing agent.
The goal of this study was to demonstrate the anticipated dual role of PMX. For this purpose we employed an established DOTA-folate conjugate (EC0800 (29) ) which was radiolabeled with
Material and Methods

Preparation of
177 Lu-EC0800. The DOTA-folate conjugate (EC0800 (29)) was kindly provided by Endocyte Inc. (Supplementary Fig. S1 ). Homburg, Germany, Supplementary Fig. S1 ). The control cells were incubated with FFRPMI medium only. After 4 h incubation at 37°C, the cells were washed once with 200 μL PBS followed by addition of FFRPMI or RPMI medium (with supplements). Cells were then allowed to grow for 4 days at 37°C without changing medium. Analysis of the viability was performed as previously reported using an MTT reagent and a microplate reader (Victor X3, Perkin Elmer) (36) . To quantify cell viability, the absorbance of the test samples was expressed as percentage of the absorbance of the control cell samples (= 100%). Dose response curves were analyzed using Table S1 ) (29) . These data sets were employed to estimate the equivalent absorbed radiation dose to the tumor xenografts and kidneys 
Results
Cancer cell lines. The human cervical KB cancer cell line is a subclone of HeLa cells (42) , known to express the FR at high very levels. IGROV-1 cells are human ovarian cancer cells which express the FR at a somewhat lower level than KB cells (12, 31, 36) . The human prostate cancer cell line PC-3 does not express the FR and was used as a negative control. These facts were confirmed in uptake/internalization studies of 177 Lu-EC0800 (Supplementary Fig. S2 ). Supplementary Fig. S4 ).
Combination index (CI
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Short after injection of 3
H-PMX the uptake in the kidneys was relatively high (~2.7% ID/g, 1 h p.i.) but a significant wash-out was observed within the following hour (~0.8% ID/g, 2 h p.i.).
In the tumor tissue accumulation of 3 H-PMX was low (~1.1% ID/g, 1 h p.i.) but more constant (0.6% ID/g, 2 h p.i.) over time. (Supplementary Methods, Supplementary Fig. S5 ).
Investigation of potential radiotoxicity. In a separate study radiotoxicity of 177 Lu-EC0800 and the kidney protective effect of a subtherapeutic amount of PMX (0.4 mg) were investigated. Nontumor bearing nude mice were monitored over 6 months. The kidney dose of 177 Lu-EC0800
(20 MBq/mouse) was ~97 Gy (group B). If PMX subther was pre-injected, the kidney dose was significantly reduced to ~24 Gy (group C). At day 50 of the study, plasma parameters of treated mice (groups B/C) were in the same range as those of control mice (group A). However, at day 130 levels of blood urea nitrogen, alkaline phosphatase and total bilirubin from mice treated with Determination of blood plasma parameters at day 180 showed the same result as found at day 130 (Table 2 ).
The extent of accumulated 99m
Tc-DMSA in the kidneys is a measure for tubular function (43) . It has previously been used as a valuable in vivo tool for monitoring kidney function during radionuclide therapy (39) . In week 3 baseline measurements of 99m Tc-DMSA uptake in the kidneys showed no significant difference among group B and group C from control mice of group A ( Fig. 2A) Tc-DMSA in mice of group B had dropped to 1.38 ± 0.16 % ID/kidney 2 h p.i. (p < 0.005), whereas in group C the uptake was still in same range as found for control animals of group A (p = 0.6) (Fig. 2C ).
Constant body weight loss was observed in mice treated with 177 Lu-EC0800 (group B) from about day 70 and thereafter. In all cases of group B the endpoint criterion which required euthanasia was reached before day 180. However, mice which had received PMX subther prior to the injection of 177 Lu-EC0800 (group C) showed body weight gain similar to the untreated controls (group A).
In vivo tumor therapy studies. The injection protocol of the therapy study with KB and IGROV-1 tumor bearing mice is shown in Figure 3A . PMX was applied either in a subtherapeutic and PMX subther (group C: 8.3 ± 3.5, p = 0.21) were not significantly different from the average RTV of control mice (group A: 10.0 ± 2.7) at day 17 (Table 3) . However, the combined application of 177 Lu-EC0800 with PMX ther resulted in a significant decrease of the average RTV (group D: 5.0 ± 2.2; p < 0.0001, Fig. 3B ). For tumor model II the average RTV of PMX treated mice (group B: 27.9 ± 11.8; p = 0.73) was not significantly reduced compared to control mice (group A: 30.0 ± 14.9) at the same time point (Table 3) . However, a significant reduction of the average RTV was observed in both groups of mice treated with 177 Lu-EC0800 (group C: 7.3 ± 3.9, p = 0.0006; group D: 2.0 ± 1.7, p = 0.0002, Fig. 3C ). Monitoring of the body weight revealed slight weight gain over time in model I and a largely constant body weight in model II ( Fig. 3D/E) . In contrast, pronounced loss of body weight was observed in group B mice of both tumor models (which received which received PMX ther only). Importantly, the average survival time was increased 75-100% in group D mice from both tumor models compared to group A mice (Table 3) .
Discussion
Combining anticancer therapies is a strategy to broaden the therapeutic index by taking an advantage of additive or synergistic antitumor effects and by reducing undesired side effects. The present study addressed the question of whether PMX contributes to the anti-tumor effect of radiofolates and prevents the risk of radionephropathy. In vitro the clonogenic potential of KB and IGROV-1 tumor cells was reduced upon exposure to 177 Lu-EC0800 in a concentration dependent manner (Fig. 1) . Moreover it was proven that this effect was specifically FR-mediated.
It was more pronounced in KB cells which express the FR at higher levels than IGROV-1 cells, and it was abolished if the cells were co-incubated with excess folic acid to block FR binding of 177 Lu-EC0800. Inhibition of cell viability through application of 177 Lu-EC0800 was enhanced if cells were co-incubated with PMX ( Fig. 1) . Determination of the combination indices at different drug concentrations revealed that 177 Lu-EC0800 and PMX provided synergistic inhibitory effects on the viability of both tumor cell lines. It was observed that incubation of the cancer cells with PMX resulted in an accumulation of the cells in the G1/S boundary or early S phase as previously reported ( Supplementary Fig. S7 ) (25, 44) . On the other hand, exposure of cells to 177 Lu-EC0800
showed a cell cycle arrest in the G2/M phase, which is a common phenomenon in eukaryotic cells exposed to ionizing radiation (45) . However, if the cancer cells were simultaneously exposed to 177 Lu-EC0800 and PMX the cell cycle arrest in G2/M phase was abrogated. Notably the disruption of the radiation-induced G2-checkpoint by chemotherapeutic agents (e.g. protein kinase inhibitors) was previously shown to sensitize cancer cells to radiation-induced apoptosis and cell death (46) (47) (48) . This mechanism might also have been responsible for PMX-induced radiosensitization of KB and IGROV-1 cells. An increased apoptotic cell fraction was measured if the cells were treated with 177 Lu-EC0800 and PMX compared to the application of each of these therapeutics alone ( Supplementary Fig. S8 ).
In vivo the pre-injection of PMX improved the tissue distribution of 177 Lu-EC0800 dramatically by increasing the tumor-to-kidney ratio (Table 1) . In an attempt to understand the underlying mechanism the uptake of 3 H-PMX was determined in KB tumors and kidneys of mice. In the kidneys we found a relatively high uptake 1 h p.i. of 3 H-PMX which was quickly cleared over time ( Supplementary Fig. S5 ). These findings together with the fact that PMX has a high affinity for the FR (49) 
